Dr. Abhigyan Upadhyay, COO, Bilcare GCS receiving ABP News Healthcare Award for best Clinical Trial Services

r. Abhigyan Upadhyay, COO, Bilcare GCS receiving ABP News Healthcare Award

Dr. Abhigyan Upadhyay, COO, Bilcare GCS with ABP News Healthcare Award

Bilcare GCS Expands Pre-Clinical and Early-Stage Development Capabilities

PHOENIXVILLE, Pa — November, 2008 — In its endeavor to accelerate the development process cycle resulting in enhanced “Speed to Market” for its clients, Bilcare Global Clinical Supplies, a leading single-source provider of Clinical Trial Supplies and services, endorses its continual capability enhancement commitment by supplementing its ability of developing functionally viable and innovative formulation dosage forms for pre-clinical and early-phase drugs.

Vincent Santa Maria, President – Bilcare GCS, Americas stated that as part of a major capital investment program at its facilities in the U.S., Bilcare GCS has added sophisticated fluid bed granulation and enhanced capsule filling technologies to its R&D Center. “With this upgrade, Bilcare GCS can now quickly produce a wider variety of drug dosage forms with high product quality at par industry benchmark. These investments in R&D services further prove our commitment to being a full-service partner to our global customers with the offering of a wide breath of specialty services, continues Vincent.”

This capability enhancement compliments the increasing number of investigational new drug (IND) applications by innovator pharma and Biotech companies, which in turn requires multi-pronged expertise, more particularly in the Formulation and Analytical research and development, commented Praful Naik, Ph.D., Chief Scientific Officer, Bilcare Limited.

The fluid-bed granulation technology extends Bilcare’s solid dosage formulation capabilities. The granulation system equipped with Wurster coating inserts enables Bilcare to develop and deliver specialized coating processes for granules and non-pareils with high precision and consistency for creation of top quality sustained and controlled-release tablet and capsule formulations.

The In-Cap® capsule system, capable of filling several thousand capsules per hour in multiple permutations, is a versatile tool for pre-clinical and early-stage development. This equipment extends both development and clinical manufacturing capabilities for a myriad of formulation types including powders, pellets, tablets and liquids.

“Bilcare’s R&D center can now develop a broad array of dosage forms with innovative delivery mechanisms, which exceeds those developed by pharmaceutical companies,” says Frank Santillo, Ph.D., Bilcare GCS’ senior director for research services. “Most importantly, we have the expertise to take a drug candidate from concept to clinical production without the client suffering critical and costly delays as a result of hand-offs, continues Frank”

About Bilcare Global Clinical Supplies

Bilcare Global Clinical Supplies serves the Americas, Europe, and Asia with clinical trial materials support, services, and complete project management. Its services for solid, semi-solid, liquid, DEA (CI-
V), and biotech clinical trial materials (CTM) satisfy a broad range of requirements; from pre-formulation research and development, manufacturing, analytical services and clinical supplies packaging and labeling, to IVRS, QP services, controlled temperature (cold chain) CTM storage, worldwide distribution, and returns and destructions accountability.

Battling fake medicines by Bilcare

http://www.forpressrelease.com/forpressrelease-364336-battling-fake-medicines-companies-such-as-bilcare-play-a-crucial-role-in-enabling-the-authentication-of-medicines.html

Battling fake medicines: Bilcare playing a Crucial role

Most of us generally take it for granted that the medicine we buy from the neighborhood chemist is genuine. For if it is not, the consequences can quickly spin out of control, even before anyone can guess what went wrong. But the uncomfortable truth is: as much as 20-25 per cent of all medicines sold in India could be counterfeit! While the precise figure varies from country to country, and from year to year, several studies have placed the proportion of fake medicines at about this level. While the nature of counterfeiting can vary: sometimes it is an insufficient quantity of medicine, or plain chalk; at other times, it’s a completely wrong medicine! But a lot of times, the manufacturing companies depend on the packaging design and reliability to differentiate the counterfeit product from the genuine. And this is where companies such as the Pune-based Bilcare Ltd play a crucial role. Bilcare’s showpiece technology is its nonClonableID, which enables products to be authenticated as they move through the supply chain to the end consumer, thus protecting brands and preventing misuse. It also provides a reliable means for effective track-n-trace and e-pedigree of products across the supply chain – from manufacturer to consumer. The nanotechnology-based system comprises a fingerprint that can be seamlessly integrated into any supply chain system. This is of critical importance because the Indian pharmaceutical market is extremely diversified; a typical medium-sized pharmaceutical manufacturer might have to deal with as many as 5,000 stockiest and distributors and perhaps 250,000 retail chemists all across the country! Clearly there is unlimited scope and opportunity for fake drugs to slip through the system. And this affects not just Indian companies but also MNC’s whose products are often cutting edge and expensive. “Bilcare’s strong research team has enabled us to expand the application of our nonClonableID technology to other sectors such as fmcg, electronic components, the auto industry and even the fashion industry,” says Bilcare founder chairman, Mohan Bhandari.

Avoiding mistakes

In addition, the company has built a variety of tiny features into the packaging materials that it offers to its pharmaceutical customers. One of them, for example, is to micro-print the manufacturer’s name in minute, barely visible, size in the form of a ring on the aluminum foil of a tablet. This enables the drug manufacturer’s audit teams to quickly identify the fake products at the distributor or even retail chemist level! Another is to create images of droplets of varying sizes and shapes on the aluminum foil, or to incorporate a change of color into the packaging material. These technologies also help to avoid mistakes by the patient or the chemist, particularly when the doctor’s prescription is misplaced, discolored or damaged in some form or other. An interesting service that the company offers its customers is known as Bilcare Optima, which helps major pharmaceuticals select the form and quality of packaging materials that would be best suited for their products. Before this was introduced, it was often seen that medicinal formulations such as tablets, capsules, etc, would either degenerate in extreme conditions because of improper packaging or the packaging cost would escalate beyond acceptable limits. Besides, if the problems were discovered after the product was submitted to the us FDA or European regulators, the entire process of documentation and filing

would have to be repeated! The expenses involved in this entire procedure would completely upset the commercial calculations of manufacturer. These product offerings, along with a range of child resistant packaging and materials that can survive wide variations of climate and temperature, have made it possible for Bilcare to attract more than 2,500 companies in over 50 countries all over the world. Over the past decade or two, they have also transformed Bilcare into a global brand. Just last month, Bilcare: was recognized as one of the Admired 100 Brands & Leaders of Asia-2014-15 by WVP World Brands for which leading management consultancy firm Ernst & Young served as process advisor. Admired 100 Asia was launched under The Asian Brand Conclave in New Delhi. The conclave was attended by luminaries of marketing, advertising, corporate leaders from different industries and backgrounds, CEO’s, Asian entrepreneurs, VIP’s and other dignitaries. Admired 100 Asia is a research based listing of 100 brands across different categories. An industry research across a total of 25 categories in Asia was conducted on an initial list of 2,000 brands and shortlisted to 100.

Reference: Business India, Magazine of the Corporate World

Bilcare Research has awarded for National Intellectual Property Award 2014

Bilcare Research has been awarded the National Intellectual Property Award 2014 by Government of India.

 

Bilcare Research has been awarded the National Intellectual Property Award 2014 by Government of India. This award is conferred to recognize and reward innovators of IP who have contributed to harnessing the country’s intellectual capital and creating an eco-system that boots creativity and innovation.
Dr. Praful R Naik, Executive Director, Bilcare was felicitated by Mr. Amitabh Kant, Secretary, DIPP at a function held on 26 April 2014, the World Intellectual Property Day, jointly organized by CII and the Government of India.

Bilcare nCiD Technology receives 2014 Frost & Sullivan India Technology Innovation Award

Mumbai, October 10, 2014:  Bilcare nonClonable ID ™ Technology was conferred with prestigious

Growth, Innovation & Leadership award 2014 by Frost & Sullivan, India. This award is conferred to recognize and reward innovation, technology and leadership best practice adopted by marquee companies across sectors. The function was attended by distinguished guests comprising innovators and visionary leaders from Corporate India.

Speaking on the occasion, Dr. Praful Naik, Ex. Director Bilcare Ltd. said:  When the world was busy in creating clones of both living and non living , Bilcare gave birth to nonClonable ID™ Technology  which today is finding applications in addressing counterfeiting in diverse industrial and governance sectors, including life saving medicines; endorsement from Frost & Sullivan is testimony to potential value that nCiD™ Technology can add across sectors for secured identity, authentication and track and trace of products and people in real time and adherence of e governance in various Government projects”.

Frost & Sullivan convened   it's 2014 annual Growth, Innovation and Leadership Executive Congress (GIL 2014: India) at the Taj Hotel in Mumbai.  This year's congress theme and focus was on recognizing emerging innovative and disruptive technologies that are radically disrupting, collapsing and transforming industries.

Frost & Sullivan's GIL Global Community continues to be the only resource in the world which supports CEOs and members of their management team with real world proven insights, tools, and strategies across more than twenty-four countries, forty-two industry verticals and market sectors and nearly one million executives around the globe.

About Bilcare Technology: 

Bilcare Technologies is a research and technology leader focused on creating next-generation anti-counterfeiting solutions. Developed with breakthrough research in nanotechnology, Bilcare’s nonClonable ID™ enables products to be authenticated as they move through the supply chain to the end consumer across varied sectors. Bilcare is firmly committed to helping its clients accomplish their business goals, whilst protecting their brands against counterfeiting


Contact :
Jaydip Chowdhury/Head corporate communications & Advocacy/Bilcare Research /020 30257791

Bilcare Recognized as Admired 100 Brands & Leaders of Asia-2014-15 by VWP World Brands and Ernst and Young as process advisor

Pune March 3: Bilcare brand Recognized as Admired 100 Brands & Leaders of Asia-2014-15 by VWP World Brands and Ernst and Young as process advisor. Admired 100 Asia was launched under The Asian Brand Conclave in New Delhi. The conclave was attended by luminaries of marketing, advertising, corporate leaders from different industries and backgrounds, CEO’s, Asian entrepreneurs, VIP’s and other dignitaries.


Admired 100 Asia is a research-based listing on 100 brands across different categories. An industry research across a total of 25 categories in Asia was conducted on an initial list of 2,000 brands and

shortlisted to 100.

Speaking on the occasion, during panel discussion on Make in India, Bilcare spokesperson said: “Bilcare has shown exemplary quality in pharmaceuticals manufacturing process and set very high standards, which has helped it to establish its brand in Asiapac. This brand recognition is testimony to our excellence in research and manufacturing, while differentiating pharmaceutical brands in the market place”

Admired 100 Asia features the journey of brands and leaders from the Asian continent involving the

regions of South East Asia, GCC Nations and the Indian Sub-Continent. It details a total of 100 Admired

brands across various categories.  Admired 100 Asia is a research based listing of these selected brands and leaders from different countries of Asian continent, it bolsters a brand’s position, value adds prominence and sets the brand apart from its competitors


Admired 100 Asia, an initiative of VWP World Brands, research by White Page International, is world’s

largest multi format platform of branding. It is an international independent platform on branding that

recognizes and pays tribute by rewarding and reinforcing the remarkable stories of the admired brands

& leaders from Asia, which has been captured in form of a coffee   table book, a dedicated portal, feature on one of the leading business channels in India.


RESEARCH METHODOLOGY & JURY:

Admired 100 Brands & Leaders of Asia-2014-15 is validated and evaluated for authenticity in research

and process, and involves the most credible list of Jury/ Patrons in the world. Below mentioned are

some of the names of the eminent honorary jury members:


1) Ms. Monica Tata- Managing Director HBO India, 2) Mr. Richard Harris- Dean Virginia Commonwealth University- Qatar, 3)  Mr. Manoj Abraham Mathew- Head Zee Network MENAP- UAE, 4)  Mr. Oliver Eills- Managing Director Publicitas UK & Middle East- UAE, 5)  Mohammad Yahya- Director Citi Group GCC Markets- UAE, 6)  Mr. Jianggan Li- Managing Director Rocket Internet GmbH- Singapore, 7)  Ms. Winnie Lyn- Leader Mindshare- Taiwan, 8)  Mr. Himanshu Shekhar- Managing Director Mindshare- Indonesia, 9)  Mr. Sunil Lulla- Chairman & Managing Director Grey Group, 11) Mr. Joseph George- CEO Lowe Lintas- India , 12) Mr. Prathap Suthan- Managing Partner Bang in the Middle- India, 13) Mr. Avinash Kaul- CEO IBN News Network


Undertaken by White Page International, Admired 100 is poised to showcase the exalting journey of the elite brands in the largest continent, Asia. The exercise features brands across 14 industries.

 A list of industries and categories was initiated, and the entire research platform was divided into regions – ASEAN, GCC, and Indian Sub-continent. A preliminary list of 2,000 brands across 14 industries and 25 sub-categories was drawn up by White Page International.


Contact:
Jaydip Chowdhury/Head corporate communications & Advocacy/Bilcare Research /020 30257791

AIT inks partnership with Bilcare nonClonableID™ Technology

The Asian Institute of Technology (AIT) in Thailand has signed a long term partnership agreement with Bilcare Limited involving multiple aspects of nanotechnology cooperation, higher education and adaptation of the path-breaking innovation - nonClonableIDTM Technology for effective use in sustainable development of the region.
Pune/ Bangkok, September 2, 2014: The Asian Institute of Technology (AIT) along with its Center of Excellence in Nanotechnology (COEN@AIT) signed a long-term agreement with Bilcare Ltd. to initiate new programs that are beneficial to both parties in a number of areas. In particular, the Memorandum of Agreement (MoU) represents the first step in the development of a unique academia-industry relationship— a model in which opportunities for technology adaptation and product development are in line with AIT’s education, training, research and regional sustainability programs. Specifically, advanced technologies like Bilcare’s nonClonableID™ (or nCiD™) technology are intended to create synergies that enable all stated objectives.  This move represents Bilcare’s first agreement with an academic institution.

Bilcare’s non-clonable identification technology was prompted by serious concerns about the drug counterfeiting industry in the region as well as globally. Fake drugs pose serious threats to health. More generally, the growing menace of a wide range of fake consumables and products also causes serious problems for manufacturers, retailers and consumers that result in lost revenues, lost taxation and of course, potential health hazards— none of which contribute in a positive way to economic viability, social development and sustainability in the region.
The nonClonableID™ exploits, in an innovative way, the intrinsic nature of composite nanoscale and microscale particulates that, when embedded onto a specialty chip substrate, yields a technology-read system that is impossible to copy— even by the inventors of the technology. During the MoU signing ceremony, Bilcare's Executive Director and Chief Scientific Officer Dr. Praful Naik said that “the nonClonableID™ technology offers real-time, ‘anywhere-anytime’ identification, authentication and product tracking and tracing, making it by far the only effective technology that is capable of providing all three components in one integrated workable system. Anti-counterfeiting, electronic-pedigree and secured tamper proof packaging are also applications involved with the technology”.
AIT President Professor Worsak Kanok-Nukulchai stated that, in addition to the MoU signing being an ‘historic’ occasion due to the novelty of the proposed academic-industry relationship, “the MoU with Bilcare earmarks the launch of a unique collaborative initiative, the ‘way forward’, between academia and industry that enables the amalgamation of domain expertise leading to localization and adaptation of state-of-the-art technologies like ‘nonClonableID™ for accomplishing the shared vision of sustainable development of the region”. The Center of Excellence in Nanotechnology will establish a technical interface program for technology evaluation, validation, testing, local adaptation and training.
Bilcare Ltd., a global leader in offering packaging solutions for the pharmaceutical industry, has sales in over one hundred countries and operates multiple R&D and manufacturing centers in Europe, the United States and Asia.
About AIT:
The Asian Institute of Technology (AIT) is an international post-graduate institute founded in 1959 and is Asia’s pioneering institute established to help meet the region’s growing need for advanced learning in the fields of engineering, science, technology and management, research and capacity building. AIT’s mission is to develop highly qualified and committed professionals that play a leading role in the sustainable development of the region and its integration into the global economy. AIT is based in Thailand and has affiliated centers and alumni in over 80 countries around the world.

http://www.bilcare.com/media/press_releases_AIT-inks-partnership-with-Bilcare.htm

Bilcare Research has been awarded the National Intellectual Property Award 2014 by Government of India

Bilcare Research has been awarded the National Intellectual Property Award 2014 by Government of India. This award is conferred to recognize and reward innovators of IP who have contributed to harnessing the country’s intellectual capital and creating an eco-system that boots creativity and innovation.
Dr. Praful R Naik, Executive Director, Bilcare was felicitated by Mr. Amitabh Kant, Secretary, DIPP at a function held on 26 April 2014, the World Intellectual Property Day, jointly organized by CII and the Government of India.

http://www.bilcare.com/media/press_releases_May_01_2014_IPAward.htm